VisEn Medical announces launch of new GastroSense 750 fluorescence agent for imaging gastric motility

April 13, 2016

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts.  VisEn offers over 30 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways.  VisEn agent brands include ProSense?, IntegriSense??, AngioSense??, OsteoSense?, MMPSense??, Annexin-VivoTM, the FAST?? line of imaging agents including Cat K FAST?? and Cat B FAST??, and now GastroSense??.  VisEn also offers specialized lines of agent labeling platforms in the red wavelength spectrum, including its proprietary VivoTag? red fluorescence labeling dyes and its NanoSpark? nanoparticles, for customized fluorescence agent labeling.  They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in biological imaging applications including cell-based and in vivo imaging applications.  

All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT??) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems.  VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems.  With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking preclinical research into clinical medicine.

SOURCE VisEn Medical Inc.